메뉴 건너뛰기




Volumn 10, Issue 7 I, 2004, Pages 445-455

Medical management of osteoporosis

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANABOLIC AGENT; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; ESTROGEN; GESTAGEN; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRIFLAVONE; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHYTOESTROGEN; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TESTOSTERONE; THYROID HORMONE; THYROTROPIN; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

EID: 3242748238     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (9)

References (112)
  • 1
    • 0035857351 scopus 로고    scopus 로고
    • Osteoporosis prevention, diagnosis, and therapy
    • NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285: 785-795.
    • (2001) JAMA , vol.285 , pp. 785-795
  • 2
    • 0030704306 scopus 로고    scopus 로고
    • Prevalence of low femoral bone density in older US adults from NHANES III
    • Looker AC, Orwoll ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768.
    • (1997) J Bone Miner Res , vol.12 , pp. 1761-1768
    • Looker, A.C.1    Orwoll, E.S.2    Johnston Jr., C.C.3
  • 3
    • 0036321486 scopus 로고    scopus 로고
    • Osteoporosis in men
    • Binkley N, Krueger D. Osteoporosis in men. WMJ. 2002;101:28-32.
    • (2002) WMJ , vol.101 , pp. 28-32
    • Binkley, N.1    Krueger, D.2
  • 4
    • 0031036671 scopus 로고    scopus 로고
    • Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation
    • Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
    • (1997) J Bone Miner Res , vol.12 , pp. 24-35
    • Ray, N.F.1    Chan, J.K.2    Thamer, M.3
  • 6
    • 0037120864 scopus 로고    scopus 로고
    • Clinical use of bone densitometry: Scientific review
    • Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889-1897.
    • (2002) JAMA , vol.288 , pp. 1889-1897
    • Cummings, S.R.1    Bates, D.2    Black, D.M.3
  • 7
    • 0034900335 scopus 로고    scopus 로고
    • American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis
    • Osteoporosis Task Force. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001;7:293-312.
    • (2001) Endocr Pract , vol.7 , pp. 293-312
  • 9
    • 0037125848 scopus 로고    scopus 로고
    • Screening for osteoporosis in postmenopausal women: Recommendations and rationale
    • US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137: 526-528.
    • (2002) Ann Intern Med , vol.137 , pp. 526-528
  • 10
    • 0032869574 scopus 로고    scopus 로고
    • Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis
    • Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int. 1999;10:259-264.
    • (1999) Osteoporos Int , vol.10 , pp. 259-264
    • Genant, H.K.1    Cooper, C.2    Poor, G.3
  • 11
    • 0036402485 scopus 로고    scopus 로고
    • What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians?
    • Binkley N, Schemeer P, Wasnich R, et al. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom. 2002;5(suppl):S19-S27.
    • (2002) J Clin Densitom , vol.5 , Issue.SUPPL.
    • Binkley, N.1    Schemeer, P.2    Wasnich, R.3
  • 12
    • 0029742361 scopus 로고    scopus 로고
    • Prevention of osteoporosis: Cost-effectiveness of different pharmaceutical treatments
    • Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int. 1996;6:265-275.
    • (1996) Osteoporos Int , vol.6 , pp. 265-275
    • Ankjaer-Jensen, A.1    Johnell, O.2
  • 13
    • 0036234263 scopus 로고    scopus 로고
    • Secondary causes of osteoporosis
    • Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77: 453-468.
    • (2002) Mayo Clin Proc , vol.77 , pp. 453-468
    • Fitzpatrick, L.A.1
  • 14
    • 0036776241 scopus 로고    scopus 로고
    • Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women
    • Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431-4437.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 4431-4437
    • Tannenbaum, C.1    Clark, J.2    Schwartzman, K.3
  • 15
    • 0026613738 scopus 로고
    • Vitamin D3 and calcium to prevent hip fractures in the elderly women
    • Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327:1637-1642.
    • (1992) N Engl J Med , vol.327 , pp. 1637-1642
    • Chapuy, M.C.1    Arlot, M.E.2    Duboeuf, F.3
  • 16
    • 0028295830 scopus 로고
    • Effect of calcium and cholecaldiferal treatment for 3 years on hip fractures in elderly women
    • Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecaldiferal treatment for 3 years on hip fractures in elderly women. BMJ. 1994;308:1081-1082.
    • (1994) BMJ , vol.308 , pp. 1081-1082
    • Chapuy, M.C.1    Arlot, M.E.2    Delmas, P.D.3
  • 17
    • 0028949069 scopus 로고
    • Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
    • Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995;98:331-335.
    • (1995) Am J Med , vol.98 , pp. 331-335
    • Reid, I.R.1    Ames, R.W.2    Evans, M.C.3
  • 18
    • 0030449017 scopus 로고    scopus 로고
    • Correcting calcium nutritional deficiency prevents spine fractures in elderly women
    • Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res. 1996;11: 1961-1966.
    • (1996) J Bone Miner Res , vol.11 , pp. 1961-1966
    • Recker, R.R.1    Hinders, S.2    Davies, K.M.3
  • 19
    • 0030763532 scopus 로고    scopus 로고
    • Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
    • Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
    • (1997) N Engl J Med , vol.337 , pp. 670-676
    • Dawson-Hughes, B.1    Harris, S.S.2    Krall, E.A.3
  • 21
    • 0032524767 scopus 로고    scopus 로고
    • Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture: A randomized, double-blind, placebo-controlled trial
    • Schurch MA, Rizzoli R, Slosman D, et al. Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:801-809.
    • (1998) Ann Intern Med , vol.128 , pp. 801-809
    • Schurch, M.A.1    Rizzoli, R.2    Slosman, D.3
  • 22
    • 0031817494 scopus 로고    scopus 로고
    • Physical activity and osteoporotic fracture risk in older women
    • Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Ann Intern Med. 1998;129:81-88.
    • (1998) Ann Intern Med , vol.129 , pp. 81-88
    • Gregg, E.W.1    Cauley, J.A.2    Seeley, D.G.3
  • 23
    • 0036048481 scopus 로고    scopus 로고
    • Exercise for preventing and treating osteoporosis in postmenopausal women
    • CD000333
    • Bonaiuti D, Shea, B, Iovine, R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2002;3: CD000333.
    • (2002) Cochrane Database Syst Rev , vol.3
    • Bonaiuti, D.1    Shea, B.2    Iovine, R.3
  • 24
    • 0037073281 scopus 로고    scopus 로고
    • Walking and leisure-time activity and risk of hip fracture in postmenopausal women
    • Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA. 2002;288:2300-2306.
    • (2002) JAMA , vol.288 , pp. 2300-2306
    • Feskanich, D.1    Willett, W.2    Colditz, G.3
  • 25
    • 0028596397 scopus 로고
    • Effects of high-intensity strength training on multiple risk factors of osteoporotic fractures
    • Nelson ME, Fiatarone MA, Morganti CM, et al. Effects of high-intensity strength training on multiple risk factors of osteoporotic fractures. JAMA. 1994;272: 1909-1914.
    • (1994) JAMA , vol.272 , pp. 1909-1914
    • Nelson, M.E.1    Fiatarone, M.A.2    Morganti, C.M.3
  • 26
    • 0028014350 scopus 로고
    • The bone density of female twins discordant for tobacco use
    • Hopper JL, Seeman E. The bone density of female twins discordant for tobacco use. N Engl J Med. 1994;330:387-392.
    • (1994) N Engl J Med , vol.330 , pp. 387-392
    • Hopper, J.L.1    Seeman, E.2
  • 27
    • 0027055405 scopus 로고
    • Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women
    • Kiel DP, Baron JA, Anderson JJ, et al. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann Intern Med. 1992;116:716-721.
    • (1992) Ann Intern Med , vol.116 , pp. 716-721
    • Kiel, D.P.1    Baron, J.A.2    Anderson, J.J.3
  • 28
    • 0343570526 scopus 로고    scopus 로고
    • Identification of early postmenopausal women with no bone response to HRT: Results of a 5-year clinical trial
    • Komulainen M, Kroger H, Tuppurainen MT, et al. Identification of early postmenopausal women with no bone response to HRT: results of a 5-year clinical trial. Osteoporos Int. 2000;11:211-218.
    • (2000) Osteoporos Int , vol.11 , pp. 211-218
    • Komulainen, M.1    Kroger, H.2    Tuppurainen, M.T.3
  • 29
  • 30
    • 0028860231 scopus 로고
    • Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women
    • Cauley JA, Seeley DG, Ensrud K, et al, Study of Osteoporotic Fractures Research Group. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995; 122:9-16.
    • (1995) Ann Intern Med , vol.122 , pp. 9-16
    • Cauley, J.A.1    Seeley, D.G.2    Ensrud, K.3
  • 31
    • 0026691295 scopus 로고
    • Treatment of postmenopausal osteoporosis with transdermal estrogen
    • Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
    • (1992) Ann Intern Med , vol.117 , pp. 1-9
    • Lufkin, E.G.1    Wahner, H.W.2    O'Fallon, W.M.3
  • 32
    • 0029907556 scopus 로고    scopus 로고
    • Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
    • Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1996;276:1389-1396.
    • (1996) JAMA , vol.276 , pp. 1389-1396
  • 33
    • 0037125379 scopus 로고    scopus 로고
    • Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
    • Rossouw JE, Anderson GL, Prentice RL, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
    • (2002) JAMA , vol.288 , pp. 321-333
    • Rossouw, J.E.1    Anderson, G.L.2    Prentice, R.L.3
  • 34
    • 0032547326 scopus 로고    scopus 로고
    • Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
    • Hulley S, Grady D, Bush T, et al, Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
    • (1998) JAMA , vol.280 , pp. 605-613
    • Hulley, S.1    Grady, D.2    Bush, T.3
  • 35
    • 0033675229 scopus 로고    scopus 로고
    • Focus on primary care postmenopausal osteoporosis: An update
    • Watts NB. Focus on primary care postmenopausal osteoporosis: an update. Obstet Gynecol Surv. 2000;55:S49-S55.
    • (2000) Obstet Gynecol Surv , vol.55
    • Watts, N.B.1
  • 36
    • 0026671983 scopus 로고
    • Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
    • Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992;305:556-561.
    • (1992) BMJ , vol.305 , pp. 556-561
    • Overgaard, K.1    Hansen, M.A.2    Jensen, S.B.3
  • 37
    • 0027931018 scopus 로고
    • A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium
    • Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest. 1994;24:565-569.
    • (1994) Eur J Clin Invest , vol.24 , pp. 565-569
    • Reginster, J.Y.1    Meurmans, L.2    Deroisy, R.3
  • 38
    • 0028914618 scopus 로고
    • Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
    • Rico H, Revilla M, Hernandez ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int. 1995;56:181-185.
    • (1995) Calcif Tissue Int , vol.56 , pp. 181-185
    • Rico, H.1    Revilla, M.2    Hernandez, E.R.3
  • 39
    • 0033829969 scopus 로고    scopus 로고
    • A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study
    • Chestnut CH III, Silverman S, Andriano K, et al, PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med. 2000;109:267-276.
    • (2000) Am J Med , vol.109 , pp. 267-276
    • Chestnut III, C.H.1    Silverman, S.2    Andriano, K.3
  • 40
    • 0036185685 scopus 로고    scopus 로고
    • Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint
    • Marcus R, Wong M, Heath H III, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002;23:16-37.
    • (2002) Endocr Rev , vol.23 , pp. 16-37
    • Marcus, R.1    Wong, M.2    Heath III, H.3    Stock, J.L.4
  • 41
    • 0026335249 scopus 로고
    • Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study
    • Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calci. tonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int. 1991;49:369-372.
    • (1991) Calcif Tissue Int , vol.49 , pp. 369-372
    • Lyritis, G.P.1    Tsakalakos, N.2    Magiasis, B.3
  • 42
    • 0033431687 scopus 로고    scopus 로고
    • Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: A prospective double-blind, randomized, placebo-controlled clinical study
    • Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain. 1999;15:284-289.
    • (1999) Clin J Pain , vol.15 , pp. 284-289
    • Lyritis, G.P.1    Ioannidis, G.V.2    Karachalios, T.3
  • 43
    • 0026010523 scopus 로고
    • Use of calcitonin in the treatment of bone pain associated with osteoporosis
    • Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int. 1991;49(suppl 2):S9-S13.
    • (1991) Calcif Tissue Int , vol.49 , Issue.SUPPL. 2
    • Gennari, C.1    Agnusdei, D.2    Camporeale, A.3
  • 44
    • 0035081522 scopus 로고    scopus 로고
    • Treatment of osteoporosis with bisphosphonates
    • Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am. 2001;27:197-214.
    • (2001) Rheum Dis Clin North Am , vol.27 , pp. 197-214
    • Watts, N.B.1
  • 45
    • 0028851590 scopus 로고
    • Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
    • Liberman UA, Weiss SR, Broll J, et al, Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995; 333:1437-1443.
    • (1995) N Engl J Med , vol.333 , pp. 1437-1443
    • Liberman, U.A.1    Weiss, S.R.2    Broll, J.3
  • 46
    • 0004851872 scopus 로고    scopus 로고
    • Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
    • Black DM, Cummings SR, Karpf DB, et al, Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
    • (1996) Lancet , vol.348 , pp. 1535-1541
    • Black, D.M.1    Cummings, S.R.2    Karpf, D.B.3
  • 47
    • 0032583492 scopus 로고    scopus 로고
    • Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
    • Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
    • (1998) JAMA , vol.280 , pp. 2077-2082
    • Cummings, S.R.1    Black, D.M.2    Thompson, D.E.3
  • 48
    • 0032896590 scopus 로고    scopus 로고
    • Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
    • Pols HA, Felsenberg D, Hanley DA, et al, Fosamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int. 1999;9;461-468.
    • (1999) Osteoporos Int , vol.9 , pp. 461-468
    • Pols, H.A.1    Felsenberg, D.2    Hanley, D.A.3
  • 49
    • 0033552255 scopus 로고    scopus 로고
    • Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
    • Harris ST, Watts NB, Genant HK, et al, Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344-1352.
    • (1999) JAMA , vol.282 , pp. 1344-1352
    • Harris, S.T.1    Watts, N.B.2    Genant, H.K.3
  • 50
    • 0035253489 scopus 로고    scopus 로고
    • Effect of risedronate on the risk of hip fracture in elderly women
    • McClung M, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;344:333-340.
    • (2001) N Engl J Med , vol.344 , pp. 333-340
    • McClung, M.1    Geusens, P.2    Miller, P.D.3
  • 51
    • 0036789682 scopus 로고    scopus 로고
    • Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence?
    • Cryer R, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77:1031-1043.
    • (2002) Mayo Clin Proc , vol.77 , pp. 1031-1043
    • Cryer, R.1    Bauer, D.C.2
  • 52
    • 0034097152 scopus 로고    scopus 로고
    • Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
    • Schnitzer T, Bone HG, Crepaldi G, et al, Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis, Aging. 2000;12:1.12.
    • (2000) Aging , vol.12
    • Schnitzer, T.1    Bone, H.G.2    Crepaldi, G.3
  • 53
    • 0037365262 scopus 로고    scopus 로고
    • Bone density changes with once weekly risedronate in postmenopausal women
    • Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom. 2003;6:45-50.
    • (2003) J Clin Densitom , vol.6 , pp. 45-50
    • Delaney, M.F.1    Hurwitz, S.2    Shaw, J.3    LeBoff, M.S.4
  • 54
    • 0036112229 scopus 로고    scopus 로고
    • Response of bone mineral density to once-weekly administration of risedronate
    • Gordon MS, Gordon MB. Response of bone mineral density to once-weekly administration of risedronate. Endocr Pract. 2002;8:202-207.
    • (2002) Endocr Pract , vol.8 , pp. 202-207
    • Gordon, M.S.1    Gordon, M.B.2
  • 55
    • 0037186928 scopus 로고    scopus 로고
    • Bisphosphonates and osteoporosis
    • Solomon CG. Bisphosphonates and osteoporosis [comment]. N Engl J Med. 2002;346:642.
    • (2002) N Engl J Med , vol.346 , pp. 642
    • Solomon, C.G.1
  • 56
    • 0037186926 scopus 로고    scopus 로고
    • Intravenous zoledronic acid in postmenopausal women with low bone mineral density
    • Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346: 653-661.
    • (2002) N Engl J Med , vol.346 , pp. 653-661
    • Reid, I.R.1    Brown, J.P.2    Burckhardt, P.3
  • 57
    • 0036679350 scopus 로고    scopus 로고
    • Meta-analyses of therapies for postmenopausal osteoporosis, IV: Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis
    • Cranney A, Tugwell P, Zytaruk N, et al, Osteoporosis Methodology Group and Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis, IV: meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:524-528.
    • (2002) Endocr Rev , vol.23 , pp. 524-528
    • Cranney, A.1    Tugwell, P.2    Zytaruk, N.3
  • 58
    • 0033581212 scopus 로고    scopus 로고
    • Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
    • Ettinger B, Black DM, Mitlak BH, et al, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
    • (1999) JAMA , vol.282 , pp. 637-645
    • Ettinger, B.1    Black, D.M.2    Mitlak, B.H.3
  • 59
    • 0034455674 scopus 로고    scopus 로고
    • Comparison of the effects of raloxifene and estrogen on bone in postmenopausal women
    • Prestwood KM, Gunness M, Muchmore DB, et al. Comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85:2197-2202.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 2197-2202
    • Prestwood, K.M.1    Gunness, M.2    Muchmore, D.B.3
  • 60
    • 0036963450 scopus 로고    scopus 로고
    • Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
    • Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87: 985-992.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 985-992
    • Johnell, O.1    Scheele, W.H.2    Lu, Y.3
  • 61
    • 0030664688 scopus 로고    scopus 로고
    • Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
    • Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
    • (1997) N Engl J Med , vol.337 , pp. 1641-1647
    • Delmas, P.D.1    Bjarnason, N.H.2    Mitlak, B.H.3
  • 62
    • 0034931645 scopus 로고    scopus 로고
    • From adjuvant therapy to breast cancer prevention: BCPT and STAR
    • Dunn BK, Ford LG. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J. 2001;7:144-157.
    • (2001) Breast J , vol.7 , pp. 144-157
    • Dunn, B.K.1    Ford, L.G.2
  • 63
    • 0035880662 scopus 로고    scopus 로고
    • Design and methods of the Raloxifene Use for the Heart (RUTH) study
    • Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol. 2001;88:392-395.
    • (2001) Am J Cardiol , vol.88 , pp. 392-395
    • Mosca, L.1    Barrett-Connor, E.2    Wenger, N.K.3
  • 65
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
    • (2001) N Engl J Med , vol.344 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 66
    • 18644374464 scopus 로고    scopus 로고
    • A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    • Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:4528-4535.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 4528-4535
    • Body, J.J.1    Gaich, G.A.2    Scheele, W.H.3
  • 67
    • 3242748818 scopus 로고    scopus 로고
    • RPhLink.com. Forteo. Available at: http://www.rphlink.com/forteo.html. Accessed August 24, 2003.
    • Forteo
  • 68
    • 0037436821 scopus 로고    scopus 로고
    • Phytoestrogens: Endocrine disrupters or replacement for hormone replacement therapy?
    • Wuttke W, Jarry H, Becker T, et al. Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? Maturitas. 2003;44:S9-S20.
    • (2003) Maturitas , vol.44
    • Wuttke, W.1    Jarry, H.2    Becker, T.3
  • 69
    • 0027177212 scopus 로고
    • Hip fracture rates in Hong Kong and the United States, 1988-1989
    • Ho SC, Bacon WE, Harris T, et al. Hip fracture rates in Hong Kong and the United States, 1988-1989. Am J Public Health. 1993;83:694-697.
    • (1993) Am J Public Health , vol.83 , pp. 694-697
    • Ho, S.C.1    Bacon, W.E.2    Harris, T.3
  • 70
    • 0032116898 scopus 로고    scopus 로고
    • Clinical Review 97: Potential health benefits of dietary phytoestrogens: A review of the clinical, epidemiological, and mechanistic evidence
    • Tham DM, Gardner CCD, Haskell WL. Clinical Review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 1998;83:2223-2225.
    • (1998) J Clin Endocrinol Metab , vol.83 , pp. 2223-2225
    • Tham, D.M.1    Gardner, C.C.D.2    Haskell, W.L.3
  • 71
    • 2042430910 scopus 로고    scopus 로고
    • Iprioflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women
    • Alexanderson P, Toussaint A, Reginster J. Iprioflavone has no effect on bone metabolism and causes lymphopenia in osteopenic women [abstract]. J Bone Miner Res. 2000;15:S198.
    • (2000) J Bone Miner Res , vol.15
    • Alexanderson, P.1    Toussaint, A.2    Reginster, J.3
  • 72
    • 0028137814 scopus 로고
    • Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate
    • Erdtsieck RJ, Van Kujik C, Birkenhager-Frenkel DH, et al. Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res. 1994;9:277-283.
    • (1994) J Bone Miner Res , vol.9 , pp. 277-283
    • Erdtsieck, R.J.1    Van Kujik, C.2    Birkenhager-Frenkel, D.H.3
  • 73
    • 0033973263 scopus 로고    scopus 로고
    • Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women
    • Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas. 2000;34:161-168.
    • (2000) Maturitas , vol.34 , pp. 161-168
    • Castelo-Branco, C.1    Vicente, J.J.2    Figueras, F.3
  • 74
    • 0029057967 scopus 로고
    • Growth hormone deficiency in adults and its response to growth hormone replacement
    • Labram EK, Wilkin TJ. Growth hormone deficiency in adults and its response to growth hormone replacement. QJM. 1995;88:391-399.
    • (1995) QJM , vol.88 , pp. 391-399
    • Labram, E.K.1    Wilkin, T.J.2
  • 75
    • 0016776460 scopus 로고
    • On an attempt to treat primary and secondary osteoporosis with human growth hormone
    • Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res. 1975;7:488-491.
    • (1975) Horm Metab Res , vol.7 , pp. 488-491
    • Kruse, H.P.1    Kuhlencordt, F.2
  • 77
    • 0030906085 scopus 로고    scopus 로고
    • Skeletal effects of cyclic recombinant growth hormone and salmon calcitonin in osteopenic postmenopausal women
    • Holloway L, Kohlmeier L, Kent K, et al. Skeletal effects of cyclic recombinant growth hormone and salmon calcitonin in osteopenic postmenopausal women. J Clin Endocrinol Metab. 1997;82:1111-1117.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 1111-1117
    • Holloway, L.1    Kohlmeier, L.2    Kent, K.3
  • 78
    • 0032452531 scopus 로고    scopus 로고
    • Association between insulin-like growth factor I and bone mineral density in older women and men: The Framingham Heart Study
    • Langlois JA, Rosen CJ, Visser M, et al. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab. 1998;83:4257-4262.
    • (1998) J Clin Endocrinol Metab , vol.83 , pp. 4257-4262
    • Langlois, J.A.1    Rosen, C.J.2    Visser, M.3
  • 79
    • 17744389368 scopus 로고    scopus 로고
    • One year of insulin-like growth factor I treatment does not affect bone density, body composition or psychological measures in postmenopausal women
    • Friedlander AL, Butterfield GE, Moynihan S, et al. One year of insulin-like growth factor I treatment does not affect bone density, body composition or psychological measures in postmenopausal women. J Clin Endocrinol Metab. 2001;86:1496-1503.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 1496-1503
    • Friedlander, A.L.1    Butterfield, G.E.2    Moynihan, S.3
  • 80
    • 0036205571 scopus 로고    scopus 로고
    • Potential use of HMG-CoA reductase inhibitors for osteoporosis
    • Cushenberry LM, de Bittner MR. Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann Pharmacother. 2002;36:671-678.
    • (2002) Ann Pharmacother , vol.36 , pp. 671-678
    • Cushenberry, L.M.1    De Bittner, M.R.2
  • 81
    • 0035725534 scopus 로고    scopus 로고
    • Boning up (or down) on statins
    • Demer LL. Boning up (or down) on statins [comment]. Arterioscler Thromb Vasc Biol. 2001;21:1565-1566.
    • (2001) Arterioscler Thromb Vasc Biol , vol.21 , pp. 1565-1566
    • Demer, L.L.1
  • 82
    • 0036190491 scopus 로고    scopus 로고
    • Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study
    • Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med. 2002;162:537-540.
    • (2002) Arch Intern Med , vol.162 , pp. 537-540
    • Pasco, J.A.1    Kotowicz, M.A.2    Henry, M.J.3
  • 83
    • 0035985878 scopus 로고    scopus 로고
    • Osteoporosis in men: Pathophysiology, evaluation, and therapy
    • Burgess E, Nanes MS. Osteoporosis in men: pathophysiology, evaluation, and therapy. Curr Opin Rheumatol. 2002;14:421-428.
    • (2002) Curr Opin Rheumatol , vol.14 , pp. 421-428
    • Burgess, E.1    Nanes, M.S.2
  • 84
    • 0030914252 scopus 로고    scopus 로고
    • Calcaneal bone mineral density predicts fracture occurrence: A five-year follow-up study in elderly people
    • Cheng S, Suominen H, Sakari-Rantala R, Laukkanen P, Avikainen V, Heikkinen E. Calcaneal bone mineral density predicts fracture occurrence: a five-year follow-up study in elderly people. J Bone Miner Res. 1997;12:1075-1082.
    • (1997) J Bone Miner Res , vol.12 , pp. 1075-1082
    • Cheng, S.1    Suominen, H.2    Sakari-Rantala, R.3    Laukkanen, P.4    Avikainen, V.5    Heikkinen, E.6
  • 85
    • 0001013799 scopus 로고    scopus 로고
    • Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds
    • Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds [abstract]. J Bone Miner Res. 2001;16:S194.
    • (2001) J Bone Miner Res , vol.16
    • Kanis, J.A.1    Johnell, O.2    Oden, A.3
  • 86
    • 0033814751 scopus 로고    scopus 로고
    • Assessing bone density in men
    • Orwoll E. Assessing bone density in men. J Bone Miner Res. 2000;15:1867-1870.
    • (2000) J Bone Miner Res , vol.15 , pp. 1867-1870
    • Orwoll, E.1
  • 87
    • 0034075945 scopus 로고    scopus 로고
    • Do men and women fracture bones at similar bone densities?
    • Selby PL, Davies M, Adams JE. Do men and women fracture bones at similar bone densities? Osteoporos Int. 2000;11:153-157.
    • (2000) Osteoporos Int , vol.11 , pp. 153-157
    • Selby, P.L.1    Davies, M.2    Adams, J.E.3
  • 88
    • 0003802711 scopus 로고    scopus 로고
    • Hyattsville, Md: National Center for Health Statistics, Dept of Health and Human Services. CD-ROM Series 11, No. 2A
    • Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey III, 1988-1994. Hyattsville, Md: National Center for Health Statistics, Dept of Health and Human Services. CD-ROM Series 11, No. 2A.
    • National Health and Nutrition Examination Survey III, 1988-1994
  • 89
    • 0030749167 scopus 로고    scopus 로고
    • Importance of albumin, 25(OH)-vitamin D and IGFBP-3 as risk factors in elderly women and men with hip fracture
    • Thiebaud D, Burckhardt P, Cosstanza M, et al. Importance of albumin, 25(OH)-vitamin D and IGFBP-3 as risk factors in elderly women and men with hip fracture. Osteoporos Int. 1997;7:457-462.
    • (1997) Osteoporos Int , vol.7 , pp. 457-462
    • Thiebaud, D.1    Burckhardt, P.2    Cosstanza, M.3
  • 91
  • 92
    • 0034739277 scopus 로고    scopus 로고
    • Alendronate for the treatment of osteoporosis in men
    • Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-610.
    • (2000) N Engl J Med , vol.343 , pp. 604-610
    • Orwoll, E.1    Ettinger, M.2    Weiss, S.3
  • 93
    • 0035187341 scopus 로고    scopus 로고
    • Alendronate treatment of established primary osteoporosis in men: Results of a 2-year prospective study
    • Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab. 2001;86:5252-5255.
    • (2001) J Clin Endocrinol Metab , vol.86 , pp. 5252-5255
    • Ringe, J.D.1    Faber, H.2    Dorst, A.3
  • 94
    • 0022758151 scopus 로고
    • Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D
    • Slovik DM, Rosenthal DI, Doppelt SH, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res. 1986;1:377-381.
    • (1986) J Bone Miner Res , vol.1 , pp. 377-381
    • Slovik, D.M.1    Rosenthal, D.I.2    Doppelt, S.H.3
  • 95
    • 0033710488 scopus 로고    scopus 로고
    • Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
    • Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-3076.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 3069-3076
    • Kurland, E.S.1    Cosman, F.2    McMahon, D.J.3
  • 96
    • 0034761548 scopus 로고    scopus 로고
    • Androgen replacement in aging men
    • Francis RM. Androgen replacement in aging men. Calcif Tissue Int. 2001;69: 235-238.
    • (2001) Calcif Tissue Int , vol.69 , pp. 235-238
    • Francis, R.M.1
  • 97
    • 0029923842 scopus 로고    scopus 로고
    • Androgen supplementation in eugonadal men with osteoporosis: Effects of 6 months of treatment on bone mineral density and cardiovascular risk factors
    • Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996;18:171-177.
    • (1996) Bone , vol.18 , pp. 171-177
    • Anderson, F.H.1    Francis, R.M.2    Faulkner, K.3
  • 98
    • 0030899249 scopus 로고    scopus 로고
    • Androgen supplementation in eugonadal men with osteoporosis: Effects of 6 months' treatment on markers of bone formation and resorption
    • Anderson FH, Francis RM, Peaston RT, et al. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months' treatment on markers of bone formation and resorption. J Bone Miner Res. 1997;12:472-478.
    • (1997) J Bone Miner Res , vol.12 , pp. 472-478
    • Anderson, F.H.1    Francis, R.M.2    Peaston, R.T.3
  • 99
    • 0030852561 scopus 로고    scopus 로고
    • Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
    • Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82: 2386-2390.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 2386-2390
    • Behre, H.M.1    Kliesch, S.2    Leifke, E.3
  • 100
    • 0035925768 scopus 로고    scopus 로고
    • Treatment of postmenopausal osteoporosis
    • Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA. 2001;285:1415-1418.
    • (2001) JAMA , vol.285 , pp. 1415-1418
    • Altkorn, D.1    Vokes, T.2
  • 101
    • 0036119735 scopus 로고    scopus 로고
    • Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs
    • Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
    • (2002) Am J Med , vol.112 , pp. 281-289
    • Cummings, S.R.1    Karpf, D.B.2    Harris, F.3
  • 102
    • 0000594779 scopus 로고    scopus 로고
    • Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women
    • Emkey R, Reid I, Mulloy A, et al. Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women [abstractl. J Bone Miner Res. 2002;17(suppl 1):S139.
    • (2002) J Bone Miner Res , vol.17 , Issue.SUPPL. 1
    • Emkey, R.1    Reid, I.2    Mulloy, A.3
  • 103
    • 0032033065 scopus 로고    scopus 로고
    • A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
    • Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med. 1998;104:219-226.
    • (1998) Am J Med , vol.104 , pp. 219-226
    • Wimalawansa, S.J.1
  • 104
    • 17744392399 scopus 로고    scopus 로고
    • Alendronate and estrogen effects in postmenopausal women with low bone mineral density
    • Bone HG, Greenspan SL, McKeever C, et al, Alendronate/Estrogen Study Group. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Enocrinol Metab. 2000;85:720-726.
    • (2000) J Clin Enocrinol Metab , vol.85 , pp. 720-726
    • Bone, H.G.1    Greenspan, S.L.2    McKeever, C.3
  • 105
    • 0033304521 scopus 로고    scopus 로고
    • Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
    • Lindsay R, Cosman F, Lobo TA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84:3076-3081.
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 3076-3081
    • Lindsay, R.1    Cosman, F.2    Lobo, T.A.3
  • 106
    • 0036963450 scopus 로고    scopus 로고
    • Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
    • Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87: 985-992.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 985-992
    • Johnell, O.1    Scheele, W.H.2    Lu, Y.3
  • 107
    • 0036962096 scopus 로고    scopus 로고
    • For osteoporosis, are 2 antiresorptive drugs better than one?
    • Ettinger B, Bilezekian JP. For osteoporosis, are 2 antiresorptive drugs better than one? J Clin Endocrinol Metab. 2002;87:983-984.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 983-984
    • Ettinger, B.1    Bilezekian, J.P.2
  • 108
    • 0037253242 scopus 로고    scopus 로고
    • Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures
    • Johnell O, Jonsson B, Jonsson L, Black D. Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003;21:305-314.
    • (2003) Pharmacoeconomics , vol.21 , pp. 305-314
    • Johnell, O.1    Jonsson, B.2    Jonsson, L.3    Black, D.4
  • 109
    • 0032726497 scopus 로고    scopus 로고
    • Current controversies in cost effectiveness analysis of osteoporosis therapies
    • Cranney A, Coyle D, Welch V, et al. Current controversies in cost effectiveness analysis of osteoporosis therapies. J Rheumatol. 1999;26:2300-2302.
    • (1999) J Rheumatol , vol.26 , pp. 2300-2302
    • Cranney, A.1    Coyle, D.2    Welch, V.3
  • 110
    • 0031791703 scopus 로고    scopus 로고
    • Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis
    • Executive Summary. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int. 1998;8 (suppl 4):S3-S6.
    • (1998) Osteoporos Int , vol.8 , Issue.SUPPL. 4
  • 111
    • 0037369962 scopus 로고    scopus 로고
    • Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: A review of the literature, 2001-2002
    • Tella MN, Feinglass J, Chang RW. Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001-2002. Curr Opin Rheumatol. 2003;15:127-131.
    • (2003) Curr Opin Rheumatol , vol.15 , pp. 127-131
    • Tella, M.N.1    Feinglass, J.2    Chang, R.W.3
  • 112
    • 0028088849 scopus 로고
    • Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly
    • Greenspan SL, Myers ER, Maitland LA, et al. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA. 1994;271: 128-133.
    • (1994) JAMA , vol.271 , pp. 128-133
    • Greenspan, S.L.1    Myers, E.R.2    Maitland, L.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.